Bradley Blaser is a Hematology physician affiliated with The Ohio State University Comprehensive Cancer Center. OpenAlex indexes 166 publications with 2,804 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
460 W 10th Ave
Columbus, OH 432101240
Telephone
614-293-3196Provider last certified this registry record 26 Feb 2026.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%BCL-2 Inhibitor100%Venclexta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2018–2025 per NIH RePORTER. The latest:
- Epigenetic control of vascular niche capacity to support hematopoiesis.
Ohio State University
FY2025$282,878R01DK128238 - Epigenetic control of vascular niche capacity to support hematopoiesis.
Ohio State University
FY2024$301,293R01DK128238 - Epigenetic control of vascular niche capacity to support hematopoiesis.
Ohio State University
FY2023$313,531R01DK128238
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- <scp>PIEZO1</scp> Activation‐Mediated Generation of Transgene‐Free Long‐Term Hematopoietic Stem Cells
American Journal of Hematology
2025 - TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppressive environment
Journal of Clinical Investigation
2025 - CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival
Cancer Immunology Immunotherapy
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Ricardo Carrau, MD
The Ohio State University Comprehensive Cancer Center
Gregory Otterson, MD
The Ohio State University Comprehensive Cancer Center
Steven Clinton, MD, PhD
The Ohio State University Comprehensive Cancer Center
Christian Rolfo, MD
The Ohio State University Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”